Atlas Trials

Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients

Clinical trial NCT04555486 · COMPLETED

Trial details

NCT number
NCT04555486
Sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Primary Hyperoxaluria Type 3
Start date
2020-09-14
Primary completion
2021-09-07
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.